K4 Elite logo K4 Elite
Home / Peptide Library / Cerebrolysin
Well Researched

Cerebrolysin

Cognitive & Neurological · ['FPF-1070', 'Cerebrolysinum']

Cerebrolysin is a peptide preparation derived from purified porcine brain proteins, studied as a neuropeptide mixture with reported neurotrophic and neuroprotective activity in models of neurological injury and dementia.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Research Level
Well Researched
Browse the store →
🧬

Cerebrolysin is a complex peptide preparation produced by the standardized enzymatic breakdown of purified porcine brain proteins. It consists of low-molecular-weight neuropeptides and free amino acids, and because it is a biological mixture it does not correspond to a single defined chemical entity or PubChem CID.

It has been studied for decades, primarily in European and Asian research settings, as a putative neurotrophic agent in the context of stroke, traumatic brain injury, and dementia. Numerous clinical trials and meta-analyses have examined its effects, with mixed and debated results.

Cerebrolysin is presented here as a research reference material. Its regulatory status varies by jurisdiction and it is not approved by the U.S. FDA.

Cerebrolysin is proposed to mimic the action of endogenous neurotrophic factors. Preclinical studies describe effects consistent with neurotrophic support, including modulation of neuronal survival signaling, reduced excitotoxicity, and effects on amyloid processing and neuroplasticity markers.

Its constituent peptides have been reported to influence pathways associated with nerve growth factor and brain-derived neurotrophic factor activity, though the precise active components of the mixture remain incompletely defined.

  • Acute ischemic stroke recovery and neuroprotection in clinical trials and Cochrane reviews (Ziganshina et al.).
  • Cognitive outcomes in vascular dementia and Alzheimer-type dementia (Gauthier et al. meta-analyses).
  • Traumatic brain injury recovery models and clinical studies (CAPTAIN trials).
  • Neurotrophic and anti-excitotoxic effects in preclinical neuronal systems.
  • Effects on neuroplasticity and amyloid-related markers in animal models.
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

A Cochrane systematic review by Ziganshina and colleagues pooled multiple randomized controlled trials of Cerebrolysin in acute ischemic stroke, using death and dependency and neurological outcome scales as measures; the review concluded the evidence did not demonstrate a clear benefit on survival and highlighted heterogeneity across trials [1].

Meta-analytic work in vascular dementia (e.g., Gauthier et al.) combined randomized trials using cognitive and global clinical rating scales (such as ADAS-cog and CGI) as outcomes and reported measurable effects on cognitive scores versus placebo in the analyzed studies [2].

The CAPTAIN traumatic brain injury studies evaluated Cerebrolysin in patients using multidimensional neurological and functional outcome batteries, applying a global-statistics analysis to assess recovery trajectory in the trial populations [3].

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

MAO inhibitorsCaution
Product literature has historically cautioned against combination with MAO inhibitors due to overlapping amino-acid metabolism considerations.
AntidepressantsCaution
Combined use with agents affecting monoamine systems is noted in prescribing literature as requiring caution.
Neurotrophic-pathway compoundsSynergistic
Proposed neurotrophic action may overlap mechanistically with other neurotrophic agents in research contexts.
Amino-acid infusionsCaution
As an amino-acid/peptide mixture, concurrent balanced amino-acid loads are a formulation consideration in study design.
  1. Ziganshina et al., Cochrane Review, Cerebrolysin for acute ischaemic stroke
  2. Gauthier et al., meta-analysis of Cerebrolysin in vascular dementia (PubMed search)
  3. CAPTAIN Cerebrolysin traumatic brain injury trial (PubMed search)
What is Cerebrolysin?
Cerebrolysin is a standardized peptide-and-amino-acid preparation derived from porcine brain proteins, studied as a neurotrophic mixture in neurological research.
Why is there no molecular formula listed?
Cerebrolysin is a complex biological mixture, not a single molecule, so it has no single PubChem CID, molecular formula, or molecular weight.
What has research examined?
Clinical trials and reviews have investigated stroke recovery, dementia-related cognition, and traumatic brain injury, with mixed and debated findings.
Is Cerebrolysin FDA approved?
No. It is not approved by the U.S. FDA; its regulatory status differs across other jurisdictions.
Can this be used as a medicine?
No. This material is supplied for laboratory research use only and is not intended to diagnose, treat, cure, or prevent any disease in humans or animals.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.